Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Chubb
Citi
UBS
Boehringer Ingelheim
Fish and Richardson
Medtronic
US Army
Cantor Fitzgerald

Generated: November 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205109

« Back to Dashboard

NDA 205109 describes VELPHORO, which is a drug marketed by Vifor Fresenius and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the VELPHORO profile page.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sucroferric oxyhydroxide profile page.
Summary for 205109
Tradename:VELPHORO
Applicant:Vifor Fresenius
Ingredient:sucroferric oxyhydroxide
Patents:2
Generic Entry Opportunity Date for 205109
Generic Entry Date for 205109*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, CHEWABLE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 205109
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VELPHORO sucroferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109 NDA Fresenius Medical Care North America 49230-645 49230-645-51 1 BOTTLE in 1 CARTON (49230-645-51) > 90 TABLET, CHEWABLE in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, CHEWABLE;ORALStrength500MG
Approval Date:Nov 27, 2013TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 19, 2018Product Flag?Substance Flag?YDelist Request?
Patented Use:CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
Patent:➤ Try a Free TrialPatent Expiration:Jan 23, 2030Product Flag?YSubstance Flag?Delist Request?
Patented Use:CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Johnson and Johnson
Harvard Business School
Julphar
Boehringer Ingelheim
Accenture
McKesson
Merck
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.